Aphria Obtains Dealer's License for International Expansion Plan

Cannabis Investing News

Aphria announced it obtained a dealer’s license pursuant to the Controlled Drugs and Substances Act under Health Canada.

Aphria (TSX:APH; OTC:APHQF) announced it obtained a dealer’s license pursuant to the Controlled Drugs and Substances Act under Health Canada.
As quoted in the press release:

This permits the Company to possess, sell and transport medical cannabis oil and resin to international markets.

“There is an incredible appetite for high-quality medical cannabis in legal markets around the world. Obtaining our Dealer’s License is a significant milestone in our international expansion strategy as it enables Aphria to have greater control over importing and exporting medical cannabis oil globally,” said Vic Neufeld, CEO of Aphria. “This license will accelerate our speed to international markets and broaden our patient base internationaly, resulting in greater revenue for Aphria.”

As mandated by Health Canada, import and export permits from the relevant international and Canadian regulatory authorities, will be required for all transactions to international markets.

Click here to read the full press release.

Source: www.newswire.ca

aphria canada health health canada patient Cannabis Investing